Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease INTRODUCTIONARIA in Alzheimer's disease backgroundOver the past decade, an active area of research has been the development of immunotherapy, with the goal of lowering cerebral amyloid beta burden in patients with Alzheimer's disease (AD).1–7 Treatment‐related amyloid‐related imaging abnormalities (ARIA) have been observed on brain imaging after treatment with some anti‐amyloid immunotherapies. The exact pathophysiology underlying ARIA remains uncertain.8–12 ARIA‐E (edema) refers to the magnetic resonance (MR) signal alterations thought to represent vasogenic edema (VE) and related extravasated fluid phenomena, whereas ARIA‐H (hemorrhage) refers to the MR signal alterations attributable to microhemorrhages, macrohemorrhages, and hemosiderosis (superficial siderosis8). ARIA‐E and ARIA‐H are typically detected on magnetic resonance imaging (MRI) sequences. Both appear to relate to the presence of cerebral amyloid angiopathy (CAA), and both occur in the natural history of AD and in the setting of amyloid‐modifying therapeutic approaches.8 Microhemorrhages naturally occur frequently in AD. Macrohemorrhages, siderosis, and edema occur only rarely in AD without treatments and are thought to be associated with CAA, but are observed at higher rates with antibody treatments. Current practice implements careful clinical and radiographic monitoring for ARIA when treating with an anti‐amyloid therapy.13RESEARCH IN CONTEXTSystematic Review: The authors reviewed the literature utilizing PubMed and recent http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Alzheimer s & Dementia Translational Research & Clinical Interventions Wiley

ARIA in patients treated with lecanemab (BAN2401) in a phase 2 study in early Alzheimer's disease

12 pages

Loading next page...
 
/lp/wiley/aria-in-patients-treated-with-lecanemab-ban2401-in-a-phase-2-study-in-06O3W1RRCx

References (62)

Publisher
Wiley
Copyright
© 2023 the Alzheimer's Association.
eISSN
2352-8737
DOI
10.1002/trc2.12377
Publisher site
See Article on Publisher Site

Abstract

INTRODUCTIONARIA in Alzheimer's disease backgroundOver the past decade, an active area of research has been the development of immunotherapy, with the goal of lowering cerebral amyloid beta burden in patients with Alzheimer's disease (AD).1–7 Treatment‐related amyloid‐related imaging abnormalities (ARIA) have been observed on brain imaging after treatment with some anti‐amyloid immunotherapies. The exact pathophysiology underlying ARIA remains uncertain.8–12 ARIA‐E (edema) refers to the magnetic resonance (MR) signal alterations thought to represent vasogenic edema (VE) and related extravasated fluid phenomena, whereas ARIA‐H (hemorrhage) refers to the MR signal alterations attributable to microhemorrhages, macrohemorrhages, and hemosiderosis (superficial siderosis8). ARIA‐E and ARIA‐H are typically detected on magnetic resonance imaging (MRI) sequences. Both appear to relate to the presence of cerebral amyloid angiopathy (CAA), and both occur in the natural history of AD and in the setting of amyloid‐modifying therapeutic approaches.8 Microhemorrhages naturally occur frequently in AD. Macrohemorrhages, siderosis, and edema occur only rarely in AD without treatments and are thought to be associated with CAA, but are observed at higher rates with antibody treatments. Current practice implements careful clinical and radiographic monitoring for ARIA when treating with an anti‐amyloid therapy.13RESEARCH IN CONTEXTSystematic Review: The authors reviewed the literature utilizing PubMed and recent

Journal

Alzheimer s & Dementia Translational Research & Clinical InterventionsWiley

Published: Jan 1, 2023

Keywords: Alzheimer's disease; anti‐amyloid; ARIA; exposure response modeling; lecanemab

There are no references for this article.